For the glioma subpopulation characterized by IDH-wild-type status, high MCT4 expression, and a high lactate burden, it is recommended that the pharmacodynamic chain—wherein lactate reduction leads to increased pH and subsequent immune activation—be validated in the preoperative window. This evidence concerns the gene IDH1 and central nervous system cancer.